parkinson, Parkinson's research notebook

Six readers

reader	found	score
genetics Open Targets	genetic association 0.32 (overall 0.25)	0.32
cell type Human Protein Atlas	cell type enhanced, including astrocytes; strongest in ependymal cells	0.75
chemistry Open Targets	hard to drug	0.00
trials ClinicalTrials.gov	no Parkinson's trials on record: an open field	1.00
literature PubMed	22 Parkinson's papers of 45	0.59
pathways Reactome	1 pathway; mostly other	0.30

No case: the score is under the bar. Receipt 1728

SNCAIP in astrocytes, braak-0.67 (p 0.047) → -0.02 (p 0.959)receipt 1734
SNCAIP in dopamine neurons, braak+0.37 (p 0.329) → -0.26 (p 0.493)receipt 1735

receipt 1735: SNCAIP in dopamine neurons, braak

power: full sample +0.05 (p 0.854, n 18), 95% CI -0.43 to +0.50. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: +0.06 (p 0.800, n 18). does not hold up.
composition: dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: +0.06 (p 0.827, n 18). could be the mix.
skeptic: leave-one-out range -0.07 to +0.17, sign flips 4; without severely affected donors +0.05 (p 0.854, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for SNCAIP in dopamine neurons.

case closed: nothing better to follow up.

receipt 1734: SNCAIP in astrocytes, braak

power: full sample -0.32 (p 0.198, n 18), 95% CI -0.68 to +0.17. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: -0.34 (p 0.161, n 18). does not hold up.
composition: astrocytes share of nuclei vs axis -0.21 (p 0.413); controlling for it: -0.27 (p 0.285, n 18). could be the mix.
skeptic: leave-one-out range -0.46 to -0.21, sign flips 0; without severely affected donors -0.32 (p 0.198, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for SNCAIP in astrocytes.

case closed: nothing better to follow up.

loading the receipts